Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity.
Maikel VerduinLinde HoosemansMaxime VanmechelenMike van HeumenJolanda A F PiepersGaluh AstutiLinda AckermansOlaf E M G SchijnsKim R KampenVivianne C G Tjan-HeijnenBuys A de BarbansonAlida A PostmaDanielle B P EekersMartijn P G BroenJan BeckervordersandforthKaterina StaňkováFrederik de SmetJeremy RichChristopher G HubertGregory GimenezAniruddha ChatterjeeAnn HoebenMarc A VooijsPublished in: Neuro-oncology advances (2023)
Overall, these findings demonstrate the robustness of PGOs in retaining the genetic and phenotypic heterogeneity in culture and the application of measuring clinically relevant drug responses. These data show that PGOs have the potential to be further developed into avatars for personalized adaptive treatment selection and actionable drug target discovery and as a platform to study GBM biology.